Page 354 - 2022_01-Haematologica-web

Letters to the Editor
of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115-2121.
4. Madan V, Shyamsunder P, Han L, et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016;30(12):2430.
5. Westervelt P, Lane AA, Pollock JL, et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression. Blood. 2003;102(5):1857-1865.
6. Bulaeva E, Pellacani D, Nakamichi N, et al. MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stim- ulus. Blood. 2020;136(24):2764-2773.
7. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002;99(1):15-23.
8.Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood. 2002;100(8):2989-2995.
9. Sternsdorf T, Phan VT, Maunakea ML, et al. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell. 2006;9(2):81-94.
10. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem. 2002;277(19):16547-16552.
11.Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001;20(8):1897-1909.
12. Toska E, Roberts SGE. Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). Biochem J. 2014;461(1):15-32.
13. Pronier E, Bowman RL, Ahn J, et al. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood. 2018;132(12):1265-1278.
14. Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation pro- filing reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841-1855.
15. Sinha S, Thomas D, Yu L, et al. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood. 2015;125(2):316-326.
16. Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its tar- get gene expression and suppress leukemia cell proliferation. Mol Cell. 2015;57(4):662-673.
346
haematologica | 2022; 107(1)